Esperion (ESPR): Growing Global Guideline Endorsements and Regulatory Milestones for Bempedoic Acid Support Buy Rating and $16 Target
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Joseph Pantginis maintains a Buy rating on Esperion with a $16 target, citing growing endorsements for bempedoic acid (BDA). BDA is recognized as a first-line LDL-C–lowering option for high-risk diabetic patients and has strong recommendations in European guidelines. Health Canada's approval and expected further international approvals support commercial growth. These factors underpin Pantginis's confidence in Esperion's potential.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments